List view / Grid view
Rheumatoid arthritis (RA) is joint-related, immune-based inflammatory disarray that affects almost 1% of the world’s population. The most evidenced pathogenesis is T-cell activation, which leads to clusters of differentiation (CD) in the T-cells and concurrently increases various inflammatory biomarkers.
The screening of drug targets against compound libraries is now a mature and validated approach to identifying the chemical starting points of drugs...
Drug resistance is a significant therapeutic problem, from infectious diseases to cancer. Given a large enough population of genetically varying target cells, the emergence of drug resistance is not surprising and is even unavoidable...
Recognised as the next wave of medicine, cell therapies have made significant strides over the last several years. But such advancements can present unique challenges, especially as more products move out of the clinic and toward commercialisation. And unlike typical pharmaceuticals, cell therapies rely heavily on the manufacturing process to…
Drug Target Review editor Steve Bremer asks David F Fischer for his views on target discovery and validation in drug discovery. David F Fischer, PhD, is Executive Director Biology at Charles River...
A range of drugs used in modern medicine are derived from animal venoms, and Steve Trim from Venomtech discusses how natural selection has made venoms particularly useful tools for uncovering new targets in drug discovery...
Human induced pluripotent stem cell derived macrophages (iPSDMs) provide a cell-based model system to study chlamydia infection in the laboratory. Amy Yeung from Wellcome Trust Sanger Institute explains how she used this model in combination with CRISPR-Cas 9 technology to explore the potential of the two genes, IRF5 and IL10RA,…
Paul Grant from Venomtech suggests that because animal venoms contain proteins and peptides that disrupt cell membrane integrity, they offer a new approach to drug discovery...
Included in this Targets In-Depth Focus: Intracellular target validation in cellular systems; New drug targets identified to defend against chlamydia infections using CRISPR and stem cells; Novel solutions for tough targets with real bite...
Included in this Stem Cells In-Depth Focus: Translating discoveries into therapies; The key to successful manufacturing of patient-specific cell therapies; Interview with Alessandro Prigione and James Adjaye...
Included in this Screening In-Depth Focus: Phenotypic and target-based screening; Killing cancer cells using clinical drug resistance; Inflammatory biomarkers as a herbal anti-arthritic drug discovery tool...
Research into innovative small molecule therapeutics with disease modifying potential in Alzheimer’s disease (AD) has been conducted at Alzheon since 2013.
Mass spectrometry (MS) performed under native-like conditions (nMS) is a promising approach for studying protein-drug interactions, and has already informed treatments of some of the most intractable diseases including cancer, diabetes and Alzheimer’s.
Since the sequence of the human genome was published some 20 years ago, omics strategies have enabled the generation of detailed molecular signatures of cancers and their subtypes.
Included in this issue: Technology convergence improves testing; Screening; Stem Cells; Targets; Mass Spectrometry; and Therapeutics in Alzheimer's disease...
